Get the Stockscreener App
18.79
0.21%
-0.04
After Hours:
18.70
-0.09
-0.48%
Dyne Therapeutics Inc stock is traded at $18.79, with a volume of 1.90M.
It is down -0.21% in the last 24 hours and up +21.62% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$18.83
Open:
$18.34
24h Volume:
1.90M
Relative Volume:
0.73
Market Cap:
$2.67B
Revenue:
-
Net Income/Loss:
$-412.89M
P/E Ratio:
-4.8679
EPS:
-3.86
Net Cash Flow:
$-361.93M
1W Performance:
+2.34%
1M Performance:
+21.62%
6M Performance:
+60.60%
1Y Performance:
-38.01%
1-Day Range:
$18.34
$19.41
1-Week Range:
$18.11
$20.07
52-Week Range:
$6.36
$31.32
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
18.79 | 2.69B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics Inc Stock Analysis and ForecastHigh Dividend Yield Stocks & Outstanding Portfolio Tips - earlytimes.in
Is Dyne Therapeutics Inc. stock attractive for long term wealth building2025 Market Sentiment & Short-Term High Return Ideas - newser.com
Dyne Therapeutics Inc. stock volume spike explainedPortfolio Return Report & Stock Portfolio Risk Management - newser.com
Is Dyne Therapeutics Inc. reversing from oversold territoryPortfolio Risk Summary & Accurate Buy Signal Alerts - newser.com
JP Morgan Maintains Dyne Therapeutics (DYN) Neutral Recommendation - Nasdaq
Will Dyne Therapeutics Inc. stock go up soonJuly 2025 Movers & High Yield Equity Trading Tips - newser.com
Why Dyne Therapeutics Inc. stock is seen as undervaluedTrade Volume Report & Real-Time Buy Zone Alerts - newser.com
Dyne Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Market Mood & Real-Time Stock Movement Alerts - newser.com
JP Morgan Lowers Price Target for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
What drives Dyne Therapeutics Inc stock priceLong-Term Investment Plans & Free Tap Rapid Wealth - earlytimes.in
Technical analysis overview for Dyne Therapeutics Inc. stock2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
How moving averages guide Dyne Therapeutics Inc. tradingJuly 2025 Final Week & Free Community Consensus Stock Picks - newser.com
Can you recover from losses in Dyne Therapeutics Inc.2025 AllTime Highs & Safe Capital Growth Tips - newser.com
Oppenheimer Maintains Dyne Therapeutics (DYN) Perform Recommendation - Nasdaq
Is Dyne Therapeutics Inc. stock entering bullish territoryTrade Signal Summary & Growth Oriented Trading Recommendations - newser.com
Dyne Therapeutics (DYN) Sees Price Target Cut by Oppenheimer | D - GuruFocus
Oppenheimer Adjusts Price Target on Dyne Therapeutics to $11 From $13, Maintains Perform Rating - MarketScreener
Will Dyne Therapeutics Inc. stock deliver better than expected guidanceTrade Risk Summary & Long-Term Capital Growth Ideas - newser.com
Analyzing Dyne Therapeutics Inc. with risk reward ratio chartsMarket Sentiment Report & Real-Time Volume Analysis - newser.com
Historical volatility pattern of Dyne Therapeutics Inc. visualizedJuly 2025 PostEarnings & Daily Price Action Insights - newser.com
Is Dyne Therapeutics Inc. stock gaining market shareDay Trade & Stepwise Swing Trade Plans - newser.com
Analysts Offer Insights on Healthcare Companies: Cencora (COR), Dyne Therapeutics (DYN) and Enhabit, Inc (EHAB) - The Globe and Mail
Can trapped investors hope for a rebound in Dyne Therapeutics Inc.Market Rally & Smart Investment Allocation Tips - newser.com
HC Wainwright & Co. Raises Price Target for Dyne Therapeutics (D - GuruFocus
Dyne Therapeutics Narrowed Losses And Eyes Major Drug Launches - Finimize
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
Dyne Therapeutics Advances in Neuromuscular Disease Therapies - TipRanks
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):